China Sterile Injectables Market Size Analysis

China Sterile Injectables Market is expected to account for over 55% of Asia Pacific share. Also, the country is the fastest growing market worldwide, expected to register double digit growth before slowing down to single digit by 2027.

Access Global Sterile Injectables Market Report and Data with Special Focus on 27+ countries: https://bekryl.com/industry-trends/sterile-injectable-market-size-analysis

The sterile injectables industry has witnessed remarkable growth in last decade with leading companies generating above average shareholder returns. Companies in the region are focusing on enhancing the product portfolio to cater to growing demand. Further, the region is highly competitive with presence of large number of regional players. Emergence of new entrants is also pushing towards competitive environment. The country is known for its high volume and low pricing differentiation. Furthermore, the overall production efficiency has increased by 7% in last five years.

Insight#1: Pfizer, Hikma, and Sagent account for majority of the China Sterile Injectables Market

Though the region is highly fragmented, Pfizer, Hikma and Sagent accounts for majority of the regional share. Recent acquisition of Hospira has helped Pfizer to further solidify its market position in China.

Insight#2: Inorganic Growth is at center of China Sterile Injectables Market Players Strategy

In last few years, there has been many mergers and acquisition to expand business presence. For instance, acquisition of Sagent by Nichi-Iko for US$ 736 million and Agila by Mylan for US$ 1,750 are primarily based on strengthening presence in South East Asia including China.

Insight#3: China Sterile Injectables Market to Register 11% Growth between 2018 and 2028

China is the fastest growing region worldwide and will register impressive 11% growth between 2018 and 2028. The region will create 2.8X higher revenue opportunity in 2028 than that in 2018. Furthermore, EBITDA margins will be significantly higher in the region.

Insight#4: Emphasis on Contract Manufacturing

The region is known for high volume with low pricing differentiation. Favorable government policies has resulted in wide scale set up of manufacturing plants across Eastern belt of China. In order to meet the end-use demand and generate high profit, leading companies are leveraging contract manufacturing model. For instance, in 2016, Taiwan Based JHL Biotech entered in agreement with PaizaBio Inc., to boost sterile injectables manufacturing in China through contract manufacturing model.

China Sterile Injectables Market Size and Forecast: Competition Landscape

Some leading sterile injectables market players in China are Pfizer, Gilead, Vanrx, GlaxoSmithKline, AstraZeneca, JHL Biotech, and Nichi-Iko. There is wide scale opportunity for industry players to capitalize the market given that the country will surpass U.S. in sales by 2020 – becoming the global leader in sterile injectable.